<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id>
<journal-id journal-id-type="publisher-id">hmg</journal-id>
<journal-id journal-id-type="hwp">hmg</journal-id>
<journal-title-group>
<journal-title>Human Molecular Genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-6906</issn>
<issn pub-type="epub">1460-2083</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26628634</article-id>
<article-id pub-id-type="pmc">4802373</article-id>
<article-id pub-id-type="doi">10.1093/hmg/ddv476</article-id>
<article-id pub-id-type="publisher-id">ddv476</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Gene-targeting pharmaceuticals for single-gene disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Beaudet</surname>
<given-names>Arthur L.</given-names>
</name>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Meng</surname>
<given-names>Linyan</given-names>
</name>
</contrib>
<aff><addr-line>Department of Molecular and Human Genetics</addr-line>, <institution>Baylor College of Medicine Houston</institution>, <addr-line>Houston</addr-line>, <addr-line>TX 77030</addr-line>, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>To whom correspondence should be addressed. Tel: +<phone>1 7137984795</phone>; Email: <email>abeaudet@bcm.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>15</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>15</day>
<month>4</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>25</volume>
<issue>R1</issue>
<issue-title>Special Review Issue: Gene Therapy</issue-title>
<fpage>R18</fpage>
<lpage>R26</lpage>
<history>
<date date-type="rev-recd">
<day>10</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>11</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Â© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="ddv476.pdf"></self-uri>
<abstract>
<p>The concept of orphan drugs for treatment of orphan genetic diseases is perceived enthusiastically at present, and this is leading to research investment on the part of governments, disease-specific foundations and industry. This review attempts to survey the potential to use traditional pharmaceuticals as opposed to biopharmaceuticals to treat single-gene disorders. The available strategies include the use of antisense oligonucleotides (ASOs) to alter splicing or knock-down expression of a transcript, siRNAs to knock-down gene expression and drugs for nonsense mutation read-through. There is an approved drug for biallelic knock-down of the <italic>APOB</italic> gene as treatment for familial hypercholesterolemia. Both ASOs and siRNAs are being explored to knock-down the <italic>transthyretin</italic> gene to prevent the related form of amyloidosis. The use of ASOs to alter gene-splicing to treat spinal muscular atrophy is in phase 3 clinical trials. Work is progressing on the use of ASOs to activate the normally silent paternal copy of the imprinted <italic>UBE3A</italic> gene in neurons as a treatment for Angelman syndrome. A gene-activation or gene-specific ramp-up strategy would be generally helpful if such could be developed. There is exciting theoretical potential for converting biopharmaceutical strategies such gene correction and CRISPR-Cas9 editing to a synthetic pharmaceutical approach.</p>
</abstract>
<funding-group>
<award-group id="funding-1">
<funding-source>NIH</funding-source>
<award-id>R01</award-id>
<award-id>HD37283</award-id>
</award-group>
<award-group id="funding-2">
<funding-source>Baylor Intellectual Disabilities Research Center</funding-source>
<award-id>1U54HD083092</award-id>
</award-group>
<award-group id="funding-3">
<funding-source>Angelman Syndrome Foundation <named-content content-type="funder-id">http://dx.doi.org/10.13039/100001951</named-content></funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>